CA1264441A - Galenical retard form - Google Patents

Galenical retard form

Info

Publication number
CA1264441A
CA1264441A CA000483768A CA483768A CA1264441A CA 1264441 A CA1264441 A CA 1264441A CA 000483768 A CA000483768 A CA 000483768A CA 483768 A CA483768 A CA 483768A CA 1264441 A CA1264441 A CA 1264441A
Authority
CA
Canada
Prior art keywords
active agent
matrix
dispersion
dispersion according
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000483768A
Other languages
English (en)
French (fr)
Inventor
Jean-Claude Gfeller
Wolfgang Czarnecki
Hans Peter Bier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of CA1264441A publication Critical patent/CA1264441A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA000483768A 1984-06-14 1985-06-12 Galenical retard form Expired CA1264441A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP3422083.6 1984-06-14
DE3422083 1984-06-14
DEP3442566.7 1984-11-22
DE3442566 1984-11-22

Publications (1)

Publication Number Publication Date
CA1264441A true CA1264441A (en) 1990-01-16

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000483768A Expired CA1264441A (en) 1984-06-14 1985-06-12 Galenical retard form

Country Status (21)

Country Link
AT (1) AT391806B (da)
AU (2) AU587190B2 (da)
BE (1) BE902626A (da)
CA (1) CA1264441A (da)
CY (1) CY1635A (da)
DE (1) DE3520184C2 (da)
DK (1) DK167649B1 (da)
ES (1) ES8702141A1 (da)
FR (1) FR2565822B1 (da)
GB (3) GB2160100B (da)
GR (1) GR851430B (da)
HK (1) HK25192A (da)
HU (1) HU198844B (da)
IE (1) IE58834B1 (da)
IL (1) IL75490A0 (da)
IT (1) IT1200080B (da)
LU (1) LU85946A1 (da)
NL (1) NL194389C (da)
NZ (1) NZ212390A (da)
PT (1) PT80635B (da)
SE (1) SE504583C2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (el) * 1988-09-30 1992-05-12 Alza Corp Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
EP1189599A2 (en) * 1999-06-11 2002-03-27 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
JP3462490B2 (ja) * 1999-08-04 2003-11-05 山之内製薬株式会社 安定な経口用医薬組成物
IL143375A0 (en) 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
CA2434835A1 (en) * 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (de) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
WO2008070118A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
MX2011001864A (es) * 2008-08-20 2011-06-20 Univ Texas Extrusion de fusion en caliente de multiples particulas de liberacion modificada.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (de) * 1967-11-17 1971-03-25 Beiersdorf Ag Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe in Form von Kapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
FI64938C (fi) * 1977-06-20 1984-02-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara bensoxa- och bensotiadiazolyl-1,4-dihydropyridinderivat
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DK154607C (da) * 1978-12-21 1989-06-05 Sandoz Ag Fremgangsmaade til fremstilling af en laegemiddelform til oral administration af ergotalkaloider
DE2904310A1 (de) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
GB8727056D0 (en) 1987-12-23
SE8502950D0 (sv) 1985-06-13
HU198844B (en) 1989-12-28
GB8514855D0 (en) 1985-07-17
FR2565822B1 (fr) 1989-02-17
GB2196852A (en) 1988-05-11
BE902626A (fr) 1985-12-10
NL194389B (nl) 2001-11-01
NL194389C (nl) 2002-03-04
PT80635A (en) 1985-07-01
ATA174885A (de) 1990-06-15
PT80635B (pt) 1987-10-20
SE504583C2 (sv) 1997-03-10
LU85946A1 (fr) 1986-01-24
GB2160100A (en) 1985-12-18
DE3520184C2 (de) 1997-03-13
GB2196852B (en) 1989-05-17
DK167649B1 (da) 1993-12-06
DK264785D0 (da) 1985-06-12
ES8702141A1 (es) 1987-01-01
HK25192A (en) 1992-04-10
DE3520184A1 (de) 1985-12-19
GB8727055D0 (en) 1987-12-23
DK264785A (da) 1985-12-15
IE851460L (en) 1985-12-14
AU4348685A (en) 1985-12-19
SE8502950L (sv) 1985-12-15
GR851430B (da) 1985-11-25
GB2196851B (en) 1989-06-07
NZ212390A (en) 1992-02-25
CY1635A (en) 1992-11-06
IL75490A0 (en) 1985-10-31
IT8548210A0 (it) 1985-06-13
AT391806B (de) 1990-12-10
GB2196851A (en) 1988-05-11
GB2160100B (en) 1989-06-01
FR2565822A1 (fr) 1985-12-20
IT1200080B (it) 1989-01-05
AU587190B2 (en) 1989-08-10
IE58834B1 (en) 1993-11-17
ES544075A0 (es) 1987-01-01
HUT40918A (en) 1987-03-30
NL8501578A (nl) 1986-01-02
AU4454389A (en) 1990-03-22

Similar Documents

Publication Publication Date Title
CA1264441A (en) Galenical retard form
JP6932746B2 (ja) エンザルタミドの製剤
CA1304294C (en) Pharmaceutical preparations with extended release
EP0097523B1 (en) Extended action controlled release compositions
US4343789A (en) Sustained release pharmaceutical composition of solid medical material
FI92903B (fi) Pitkävaikutteisen farmaseuttisen valmisteen valmistusmenetelmä
KR101512404B1 (ko) 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법
EP3257500A1 (en) Apixaban formulations
US5268182A (en) Sustained-release drug dosage units of terazosin
EP1833466A1 (en) Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
JP2002517431A (ja) マイクロ浸透圧制御薬物送達システム
NZ233954A (en) Sustained release pharmaceutical composition comprising 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridine carboxylic acid isopropyl ester
KR890001501B1 (ko) 조절된 서방성을 지닌 활성제의 고형분산액 제조방벙
CH670201A5 (en) Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
US20050215455A1 (en) Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them
SK11072000A3 (sk) Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami
JPS6110507A (ja) 新規遅効性製剤
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole

Legal Events

Date Code Title Description
MKEX Expiry